Cellectis' Annual Shareholders' General Meeting to be Held on June 28, 2022
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its combined general meeting on June 28, 2022 at 2:30 p.m. CET at the Company's offices at 8 rue de la Croix Jarry (4th floor) 75013 Paris, France.
The notice announcing the General Meeting details the agenda and modalities of participation for the meeting, and will be made available on the Company’s website: https://cellectis.com/en/investors/general-meetings/
For more information, visit www.cellectis.com
For further information, please contact:
Investor Relation contact: